A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A
Durvalumab consolidation after daily carboplatin with radiotherapy was effective and tolerable for LA-NSCLC vulnerable patients.
Authors
- Kazuya Yoshimura (ORCID: https://orcid.org/0000-0001-8842-8260)
- Ryo Ko (ORCID: https://orcid.org/0000-0002-2551-3529)
- Makoto Maemondo (ORCID: https://orcid.org/0000-0002-1950-1943)
- Hiroshi Kagamu (ORCID: https://orcid.org/0000-0003-4523-8517)
- Tomonori Makiguchi (ORCID: https://orcid.org/0000-0001-9249-7904)
- Minoru Akiyama (ORCID: https://orcid.org/0000-0002-9757-8874)
- Kunihiko Kobayashi (ORCID: https://orcid.org/0000-0002-6468-9068)
- Taku Nakagawa (ORCID: https://orcid.org/0000-0003-1281-2412)
- Shingo Kato (ORCID: https://orcid.org/0000-0002-6699-9334)
- Akira Kisohara
- K. Kaira
- Kazutoshi Isobe (ORCID: https://orcid.org/0000-0002-9995-2217)
- Ryo Morita (ORCID: https://orcid.org/0000-0002-4746-3163)
- Ryosuke Honda (ORCID: https://orcid.org/0000-0002-0707-0971)
- Akihiro Bessho (ORCID: https://orcid.org/0000-0002-0394-7377)
- Toru Kondo (ORCID: https://orcid.org/0000-0001-6853-7574)
- Atsuto Mouri (ORCID: https://orcid.org/0000-0001-8704-8151)
- N. Ishikawa
Institutions
- Toho University (JP)
- Jichi Medical University (JP)
- Hirosaki University (JP)
- Iwate Medical University (JP)
- Kanagawa Prefectural Hospital Organization (JP)
- Nagoya City University (JP)
- Shizuoka Cancer Center (JP)
- Hiroshima Prefectural Hospital (JP)
- Okayama Red Cross General Hospital (JP)
- Saitama International Medical Center (JP)
- Akita Industrial Technology Center (JP)
- Asahi General Hospital (JP)
- Kanagawa Cancer Center
- Saitama Medical University (JP)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103939
- Citations
- 5
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- AstraZeneca